Home >> Top News >> Abbott closes deal on Alere

Abbott closes deal on Alere

Print Friendly, PDF & Email

Oct. 9, 2017Abbott successfully completed its purchase of Alere on Oct. 3. The deal originally began in February 2016, when the companies first announced the purchase agreement.

“Creating the world’s leading point-of-care business will help Abbott meet the growing demand for fast, accurate, and actionable information,” Brian Blaser, executive vice president of diagnostics products for Abbott, said in a statement. “Combined with Abbott’s existing point of care business and its leading hand-held platform, i-STAT, we now have the broadest point-of-care testing portfolio to help improve care for patients in more parts of the world.”

With the addition of Alere, Abbott has approximately $7 billion in diagnostics sales worldwide, including approximately $2.5 billion in point-of-care testing, according to a statement from Abbott.

More top news


Check Also

Sanquin selects Alinity s for blood, plasma screening

June 2018—Sanquin and Abbott announced they signed a multiyear contract for the supply of primary serological equipment and consumables, including Abbott’s Alinity s system, for blood and plasma screening.